Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. (2011)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(11)60756-3

PubMed Identifier: 21784508

Publication URI: http://europepmc.org/abstract/MED/21784508

Type: Journal Article/Review

Volume: 378

Parent Publication: Lancet (London, England)

Issue: 9791

ISSN: 0140-6736